Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (K01 NS096719-01)
National Institute on Aging (AG04867801)
Received: 28 May 2019
Accepted: 9 October 2019
First Online: 22 October 2019
: All experiments were conducted under the institutional guidelines and were approved by the Institutional Animal Care and Use Committee at Washington University School of Medicine.
: GG, HJ, CL, and DMH are listed as inventors on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. DMH co-founded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N Diagnostics, LLC has licensed certain anti-tau antibodies to AbbVie for therapeutic development. DMH is on the scientific advisory board of Denali and Genentech and consults for Idorsia.